Search clinical trials for: Non-Small-Cell Lung,radiotherapy, Chemotherapy, vinorelbine

Total 675 results

Bristol-Myers Squibb

Withdrawn

An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease (CheckMate 9TN)

Non-Small Cell Lung Cancer | Non-Small-Cell Lung Carcinoma | Circulating Tumor DNA
El Kendi Pharmaceuticals Manufacturing Company

Completed

Evaluate Efficacy of the Association Nimotuzumab(HR3) /Cisplatin-Vinorelbine on Patients With Cervical Carcinom (CIMAHOPE)

Cervical Cancer

Algeria
Pierre Fabre Pharma GmbH
Winicker Norimed GmbH

Completed

Initial Oral Vinorelbine Dosing Schedules in Clinical Routine in Germany and Austria (StepUp)

Breast Cancer | Non-Small-Cell Lung Cancer

Germany, Austria
Eli Lilly and Company

Completed

Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer

Carcinoma | Lung Neoplasms | Non-Small-Cell Lung Carcinoma | Cancer of the Lung

United States, Canada, Puerto Rico
Duke University
Eli Lilly and Company

Terminated

Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer (TOP0703)

Carcinoma, Non-Small-Cell Lung

United States
Hellenic Oncology Research Group
University Hospital of Crete

Terminated

Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer

Non-Small-Cell Lung Cancer

Greece
University Hospital, Brest
Fabre Clinic

Completed

Oral Vinorelbine and Cisplatin and Concurrent Radiotherapy After Induction Chemotherapy in Locally Advanced NSCLC. (VINCR)

Lung Neoplasm

France
AstraZeneca

Completed

Phase II Iressa Versus Vinorelbine (INVITE)

Non-Small-Cell Lung Carcinoma

Czech Republic, Italy, Korea, Republic of, South Africa, United Kingdom, Germany, Australia, Taiwan, France, Brazil
Aktion Bronchialkarzinom e.V.

Completed

Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy.

Non-Small-Cell Lung Carcinoma

Germany
Chinese PLA General Hospital

Not yet recruiting

Chidamide+Decitabine Plus Anti-PD-1 Antibody in PD-1 Inhibitor Failed Patients With Classical Hodgkin Lymphoma.

PD-1 Inhibitor Failed Patients With Classical Hodgkin Lymphoma
Shanghai Escugen Biotechnology Co., Ltd

Not yet recruiting

A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Metastatic Breast Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Triple-Negative Breast Cancer

China
Memorial Sloan Kettering Cancer Center
Seagen Inc.

Recruiting

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Hodgkin Lymphoma

United States
Fudan University

Not yet recruiting

Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer

Triple-negative Breast Cancer
Fudan University

Not yet recruiting

Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer

Triple-negative Breast Cancer
Jemincare

Not yet recruiting

Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects

Solid Tumor, Adult
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer

HR+HER2- Breast Cancer

China
Avistone Biotechnology Co., Ltd.

Recruiting

Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI

Non-Small-Cell Lung Cancer

China
Guangzhou Institute of Respiratory Disease

Recruiting

Oral Chemotherapeutic Drugs Were Analyzed in Patients With Driver Gene Negative Locally Advanced/Advanced Non-small Cell Lung Cancer With PS Score 2 A Prospective, Single-arm, Multicenter, Observational Study on the Efficacy and Safety of Radiochemotherapy Combined With PD-1 Inhibitor

Non-small Cell Lung Cancer Stage IIIB/IV

China
Avistone Biotechnology Co., Ltd.

Not yet recruiting

Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.

Non-Small-Cell Lung Cancer
Sun Yat-sen University

Recruiting

Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer

Breast Cancer | Refractory Breast Carcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Breast Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer

Breast Cancer | Triple Negative Breast Cancer
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Chi-GVM Regimen for the Treatment of R/R PTCL

Relapsed/Refractory Peripheral T-cell Lymphoma

China
AstraZeneca
Yghea

Recruiting

Acalabrutinib Real World Italian obSErvational Study -ARISE (ARISE)

Chronic Lymphocytic Leukemia

Italy
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer

Metastatic Breast Cancer | Advanced Malignancies | Recurrent Breast Cancer

China
Cancer Institute and Hospital, Chinese Academy...
Dizal Pharmaceuticals

Not yet recruiting

Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC) (JACKPOT33)

Non-Small-Cell Lung Cancer

China
Henan Cancer Hospital

Not yet recruiting

Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial

Advanced Breast Cancer | Treatment | HR Low/HER2 Negative
Shanghai Yizhong Pharmaceutical Co., Ltd.

Recruiting

Paclitaxel Polymeric Micelles for Injection Versus TPC on the Treatment of HER2-negative Metastatic Breast Cancer (MBC).

Metastatic Breast Cancer (MBC)

China
University of Salamanca

Not yet recruiting

QOL After SURGERY and ADJUVANT Treatment

Quality of Life | Carcinoma, Non-Small-Cell Lung

Spain
Guangdong Provincial People's Hospital
Sun Yat-sen University; First Affiliated Hospital, Sun Yat-Sen University; Shantou...

Recruiting

Organoid-based Functional Precision Therapy for Advanced Breast Cancer (ORIENTA)

Advanced Breast Cancer | HER2-negative Breast Cancer

China
Sichuan Kelun Pharmaceutical Research Institute...

Not yet recruiting

A Phase III Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer

Metastatic Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Not yet recruiting

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

Breast Cancer

China
St. Jude Children's Research Hospital

Recruiting

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

Rhabdomyosarcoma

United States
Yan Xue

Recruiting

Efficacy and Safety of Metronomic Oral Vinorelbine Plus Anlotinib in HER2-negative Metastatic Breast Cancer Patients

Breast Cancer

China
Avistone Biotechnology Co., Ltd.

Recruiting

A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC) (Kannon)

Non-Small-Cell Lung Cancer

China
Eli Lilly and Company

Recruiting

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer (CAMPFIRE)

Adolescent | Neoplasms | Child

United States, Spain, United Kingdom, Australia, Italy, Japan, Belgium, France, Germany
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

DP303c in Patients With HER2-positive Advanced Breast Cancer

HER2-positive Advanced Breast Cancer
US Oncology Research

Recruiting

MYLUNG Consortium Part 3: Observational Study (MYLUNG)

Carcinoma, Non-Small-Cell Lung

United States
Zhejiang Cancer Hospital

Recruiting

Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABC (HER2-VIP)

HER2-positive Advanced Breast Cancer

China
University of Miami

Recruiting

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Breast Cancer | Metastatic Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer

United States
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer

Breast Cancer

China
Fudan University

Recruiting

Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer (BCTOP-T-M01)

Triple-Negative Breast Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer

Breast Neoplasms

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer

Breast Cancer

China
Boehringer Ingelheim
Universitätsklinikum Kiel, Onkologisches Zentrum

Recruiting

A Study to Compare Tissue and Liquid Biopsies in People With Different Types of Cancer

Colorectal Cancer | Pancreatic Ductal Adenocarcinoma | Non-Small-Cell Lung Carcinoma

Germany
Novartis Pharmaceuticals

Recruiting

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

Non-Small-Cell Lung Carcinoma

Korea, Republic of
Fujian Cancer Hospital

Not yet recruiting

Almonertinib Plus Metronomic Oral Vinorelbine

NSCLC | EGFR | Third-generation TKI
National Research Center for Hematology, Russia

Recruiting

Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma

Hodgkin Lymphoma

Russian Federation
Sichuan Academy of Medical Sciences
Sichuan Provincial People's Hospital

Recruiting

Direct Endovascular Treatment Versus Bridging Treatment In Basilar Artery Occlusive Stroke (BEST-BAO)

Thrombosis | Acute Ischemic Stroke | Basilar Artery Occlusion | Endovascular Treatment | Alteplase

China

3

Subscribe